Atlas Trials

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

Clinical trial NCT02960204 · COMPLETED

Trial details

NCT number
NCT02960204
Sponsor
Histogen
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
CirrhosisPortal HypertensionNon-alcoholic Steatohepatitis
Start date
2016-10-17
Primary completion
2018-10-02
Enrollment
263

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.